JeanMarie Guenot is the manager of the well-known Amphivena Therapeutics. She trained in physical and medicinal chemistry, majoring in quantum mechanical and semi-empirical methods for molecular dynamics, X-ray and NMR refinement, protein structure prediction, and drug design. She got her MBA from Wharton School, University of Pennsylvania and a Ph. D. from the University of California. Guenot boasts over 20 years’ experience in pharmaceutical and biotechnology industry. She founded and managed the SKS Ocular. She also served as the co-head of Corporate & Business Development unit at PDL BioPharma, according to her website: http://jeanmarieguenot.com/
Guenot’s fruitful scientific career commenced at Hoffman-La Roche, where she worked as the principal scientist in Preclinical R&D. Her responsibility was to develop drugs for metabolic & autoimmune diseases, inflammation, and oncology. Guenot’s business career, on the other hand, can be traced back at Atlas Ventures, where she managed venture capital investments. JeanMarie Guenot also served as the Hoffman-La Roche business adviser in Basel and Shanghai China between 2008 and 2009. In 2005, the Bio Business Network honored her with the BioBusiness Network Innovative Bio-Partnering Award. A year later, she received a deal of distinction from the Licensing Executives Society.
Amphivena Therapeutics Inc. is a company based in San Francisco that specializes in developing bi-functional antibody remedies for hematologic malignancies. The company is currently developing an innovative antibody therapy aimed at eradicating blood cancer. In a Series A financing led by MPM Capital, Amphivena Therapeutics garnered over $14 Million in July 2013. In 2015, the company hit yet another milestone by selecting a clinical candidate for further development in hematologic malignancies against an undisclosed tumor.
Contribution to Society
Through her inventions, JeanMarie Guenot has immensely impacted on the lives of many people. She has discovered drugs that cure inflammation and autoimmune diseases. She has led the fight against diseases like cancer through her commitment to research and drug development.
Presence on social media
Most of JeanMarie’s Facebook and Twitter posts are about her discoveries. Case in point, she tweeted about AMV564, a drug she recently discovered that could serve as a treatment for myeloid Leukemia.